Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.

No abstract is available for this paper.

• Publication year

  1977

• Venue

  American Journal of Medicine

• Publication date

  1977-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0002-9343(77)90543-5PMID 605911
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognosis of myelomatosis on treatment with prednisone and cytostatics.

  2009cited by this paper
• Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse.

  1976cited by this paper
• Early recruitment in the human myeloma cell population after cytostatic treatment.

  1976cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper
• Expansion of the growth fraction in multiple myeloma with alkylating agents.

  1975cited by this paper
• Treatment of plasma cell myeloma with cytotoxic agents.

  1975cited by this paper
• Cellular kinetics in multiple myeloma. A new approach to staging and treatment.

  1975cited by this paper
• Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.

  1975cited by this paper
• Prognostic factors in multiple myeloma

  1975cited by this paper
• DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy.

  1974cited by this paper
• Effect of chemotherapy on the labelling index of myeloma cells

  1974cited by this paper
• Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU

  1974cited by this paper
• Immunoglobulin synthesis and tumor kinetics of multiple myeloma.

  1973cited by this paper
• Immunoglobulin synthesis and tumor kinetics of multiple myeloma.

  1973cited by this paper
• Kinetics of tumor growth and regression in IgG multiple myeloma.

  1972cited by this paper
• Plasma cell myeloma. An interpretive review

  1972cited by this paper
• Combination chemotherapy for multiple myeloma

  1972cited by this paper
• Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.

  1972cited by this paper
• Procarbazine (NSC-77213) and multiple myeloma.

  1970cited by this paper
• Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma.

  1970cited by this paper
• Growth Rates and Responses to Treatment in Human Myelomatosis

  1969cited by this paper
• Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.

  1969cited by this paper
• Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.

  1969cited by this paper
• Clinical trials with N‐isopropyl‐α‐(2‐methylhydrazino)‐p‐toluamide hydrochloride in malignant lymphoma and other disseminated neoplasia

  1967cited by this paper
• A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

  1965cited by this paper
• A generalized two-sample Wilcoxon test for doubly censored data.

  1965cited by this paper
• MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS.

  1964cited by this paper
• Comparison of effect of cyclophosphamide and a placebo in treatment of multiple myeloma.

  1963cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Venereal disease in British West Africa.

  1947cited by this paper

• Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure

  2025cites this paper
• Revisiting the Role of Alkylating Agents in Multiple Myeloma: Up-to-Date Evidence and Future Perspectives.

  2023cites this paper
• Inhibiting γ-secretase in myeloma tumor cells to improve killing by chimeric antigen receptor T cells

  2017cites this paper
• Multiple myeloma

  2017cites this paper
• Biological markers and treatment as prognostic factors in multiple myeloma

  2015cites this paper
• THERAPY FOR MULTIPLE MYELOMA - HISTORICAL PERSPECTIVE: REVIEW OF LITERATURE

  2015cites this paper
• Traitement du myélome multiple

  2013cites this paper
• analysis of 123 treated patients A new improved clinical staging system for multiple myeloma based on

  2011cites this paper
• History of multiple myeloma.

  2011cites this paper
• Effect of cobalt‐60 (γ radiation) on multidrug‐resistant multiple myeloma cell lines

  2011cites this paper
• alkylating-agent therapy: a study of the CALGB Improved survival of increased-risk myeloma patients on combined triple-

  2011cites this paper
• antibodies and magnetic immunobeads Elimination of myeloma cells from bone marrow by using monoclonal

  2011cites this paper
• Evaluation of Serial Bone X‐ray Examination in Multiple Myeloma

  2009cites this paper
• The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.

  2009cites this paper
• Critical study of staging in multiple myeloma.

  2009cites this paper
• Treatment of advanced bone marrow neoplasms with ifosfamide combinations.

  2009cites this paper
• Myeloma-associated cardiac amyloidosis. A case report.

  2009cites this paper
• Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.

  2009cites this paper
• Newly diagnosed multiple myeloma in Taiwan

  2009cites this paper
• Improved survival in multiple myeloma with renal failure.

  2009cites this paper
• Bone marrow transplantation in multiple myeloma.

  2009cites this paper
• Triple MEL100 therapy in multiple myeloma.

  2009cites this paper
• Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents.

  2009cites this paper
• Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.

  2009cites this paper
• Multiple Myeloma – inching towards a cure

  2009cites this paper
• [Systemic light-chain disease as a complication of plasmacytoma].

  2008cites this paper
• Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma

  2006cites this paper
• Complete response in multiple myeloma

  2006cites this paper
• The Effect of Inhibition of Glutothione Reductase on the Detoxification of H 2 O 2 by Rabbit Lens

  2005cites this paper
• Allogeneic transplantation and treatment with donor lymphocytes

  2004cites this paper
• Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol

  2004cites this paper
• Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma

  2004cites this paper
• Multiple myeloma: differential diagnosis and prognosis

  2004cites this paper
• Original article Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma

  2004cites this paper
• Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I–II trial

  2004cites this paper
• Treatment of Multiple Myeloma

  2004cites this paper
• Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment.

  2003cites this paper
• Multiple myeloma and other plasma cell dyscrasias

  2003cites this paper
• Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease.

  2003cites this paper
• Treatment of multiple myeloma

  2003cites this paper
• Advances in the Biology and Treatment of Multiple Myeloma

  2003cites this paper
• Effect of H(2)O(2)on human lens epithelial cells and the possible mechanism for oxidative damage repair by thioltransferase.

  2002cites this paper
• Extended Survival in Advanced-Stage Multiple Myeloma Patients Treated with Gallium Nitrate

  2002cites this paper
• Management of patients with multiple myeloma: emphasizing the role of high-dose therapy.

  2001cites this paper
• Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasone

  2001cites this paper
• Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma.

  2001cites this paper
• Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report

  2000cites this paper
• 20th‐Century Advances in Drug Therapy in Oncology—Part II

  2000cites this paper
• Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma

  2000cites this paper
• Intravenous Melphalan and Dexamethasone Followed by Lymphoblastoid Alpha Interferon in Higher Risk Multiple Myeloma Patients

  2000cites this paper
• Potent Induction of Apoptosis by β-Lapachone in Human Multiple Myeloma Cell Lines and Patient Cells

  2000cites this paper
• OPP-EBV-CAD Regimen as Salvage Treatment in Advanced Refractory or Resistant Multiple Myeloma

  2000cites this paper
• Estrogen receptors in human myeloma cells.

  2000cites this paper
• 20th‐Century Advances in Drug Therapy in Oncology—Part I

  2000cites this paper
• The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma

  1999cites this paper
• Current Drug Therapy for Multiple Myeloma

  1999cites this paper
• Treatment of multiple myeloma.

  1999cites this paper
• High-dose therapy in multiple myeloma and primary amyloidosis: an overview.

  1999cites this paper
• Conventional Chemotherapy for Multiple Myeloma

  1999cites this paper
• Human myeloma cell apoptosis induced by interferon-alpha.

  1998cites this paper
• The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.

  1998cites this paper
• ロ多発性骨髄に対するvincristine, cyclophosphamide, prednisolone (± interferon-a) 併用療法の治療成績

  1998cites this paper
• Multiple myeloma: A patient with unusual features including intracranial and meningeal involvement, testicular involvement, organomegaly, and plasma cell leukemia

  1998cites this paper
• [The efficacy of polychemotherapy programs in treating multiple myeloma patients].

  1998cites this paper
• Effect of the nitrosourea anti-tumor chemotherapeutical agent MCNU on five human myeloma cell lines.

  1998cites this paper
• Human myeloma cell apoptosis induced by interferon‐α

  1998cites this paper
• Management of Myeloma: Current and Future Approaches.

  1998cites this paper
• Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations

  1998cites this paper
• Treatment of multiple myeloma

  1998cites this paper
• Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial.

  1998cites this paper
• Multiple myeloma: clinical evaluation of plasma cell lymphoproliferative disorders and initial management.

  1997cites this paper
• Treatment Strategies in Multiple Myeloma: Biotherapy with Interferons

  1997cites this paper
• Multiple myeloma: prognosis and standard treatment.

  1997cites this paper
• Diagnosis, prognosis, and standard treatment of multiple myeloma.

  1997cites this paper
• [Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone].

  1997cites this paper
• Treatment of Multiple Myeloma in Elderly Patients

  1997cites this paper
• Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma.

  1997cites this paper
• Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations

  1997cites this paper
• Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma

  1997cites this paper
• Prophylactic antibiotics for the prevention of early infection in multiple myeloma.

  1996cites this paper
• The waning war on cancer.

  1995cites this paper
• Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).

  1995cites this paper
• High proportions of VLA‐5− immature myeloma cells correlated well with poor response to treatment in multiple myeloma

  1995cites this paper
• Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma.

  1995cites this paper
• Treatment of primary amyloidosis.

  1995cites this paper
• Development of a criterion for response to therapy at 6 months in multiple myeloma

  1995cites this paper
• Multiple Myeloma

  1995cites this paper
• Prognostic factors in low tumour mass asymptomatic multiple myeloma: A report on 91 patients

  1995cites this paper
• Multiple myeloma: current treatment.

  1994cites this paper
• Standard treatment of multiple myeloma.

  1994cites this paper
• Studies on the effect of chemotherapy for multiple myeloma with analysis of bone lesion

  1994cites this paper
• The treatment of multiple myeloma--an important MRC trial.

  1994cites this paper
• [Acute plasma cell leukemia. Clinical course during high-dose melphalan therapy].

  1993cites this paper
• Paresthesia of the mandibular division, trigeminal nerve.

  1993cites this paper
• Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study.

  1993cites this paper
• Advances in the treatment of multiple myeloma.

  1993cites this paper
• A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma.

  1993cites this paper
• [Mobilization of circulating hematopoietic stem cells by granulocyte colony stimulating factor after chemotherapy in multiple myeloma].

  1993cites this paper
• Immunoglobulin-A plasma cell dyscrasia in a young Hispanic man.

  1993cites this paper
• Biology and treatment of multiple myeloma.

  1993cites this paper